跳至主要内容
临床试验/NCT01377870
NCT01377870已完成1 期

Effect and Side Effect of Mesenchymal Stem Cell in Multiple Sclerosis

Royan Institute1 个研究点 分布在 1 个国家目标入组 22 人开始时间: 2011年12月1日最近更新:
适应症
干预措施

试验速览

阶段
1 期
状态
已完成
入组人数
22
试验地点
1
主要终点
MRI metrics changes

研究概览

简要总结

Multiple sclerosis is a multifocal inflammatory disease of the central nervous system which affects young individuals and causes paralysis of the limbs, sensation, visual and sphincter problems. The disease is caused by an autoimmune mechanism, ie the immune system produces antibodies and cells which attack the self myelin antigens, causing therefore demyelination. The disease is clinically evident with relapses of neurological disability due to the dysfunction of the areas (plaques of multiple sclerosis) in which damage of myelin occurs. Disability can accumulate with time and the disease enters a progressive phase due to damage of the axons and irreversible neurodegeneration. Although, effective immunotherapies exist which downregulate the autoimmune anti-myelin reactivity and reduce the rate of relapses of MS (like Copaxone and interferons), there is no effective means today to stop the progression of disability and induce rebuilding of the destroyed myelin.Adult bone marrow derived stromal cells (MSC) were shown to induce similar (to the neuronal stem cells) immunomodulatory and neuroregenerative effects and were shown in our laboratory to induce neuroprotection in the animal model of chronic experimental autoimmune encephalomyelitis (EAE). These bone marrow derived MSCs offer practical advantages for clinical therapeutic applications, since they can be obtained from the adult bone marrow and therefore the patient can be the donor for himself, without any danger for rejection of the cells. In addition, MSCs carry a safer profile and are less prone to malignant transformation.

Our center will perform a clinical trial with intra venous transplantation of bone marrow derived mesenchymal stem cell.our purpose is to evaluate the safety and feasibility of cell transplantation after 1year following up.

详细描述

In the clinical trial 30 patients with multiple sclerosis who are drug resistance will take apart.Based on inclusion and exclusion criteria patients are chosen.Bone marrow aspiration will be done for all of them under local anesthesia.Patients are randomly divided in 2 groups:case and control. Then mesenchymal stem cells which are separated and prepared will be transplanted by intravenous injection to the patients in case group and the cells which obtain from patients in control group are frozen and inject after 6 months. Patients will be followed by Evaluation of EDSS MSFC RAO Test brain and cervical MRI and quality of life questionnaire after 1th 3th 6th and 12th months after transplantation.all these tests will be done before transplantation as basic evaluation.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Double (Participant, Investigator)

入排标准

年龄范围
18 Years 至 55 Years(Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Both gender
  • •Age: 18-55years
  • •Duration of disease: 2-10 years
  • •Relapsing remitting with drug resistance
  • •EDSS: 3-6.5
  • •Resistance to immunomodulatory and cytotoxic drugs:
  • •At least 1-2 sever relapse during 1 year drug treatment
  • •At least increase 1 point of EDSS during 1 year drug treatment
  • •Secondary progressive or relapsing multiple sclerosis
  • •Primary progressive MS with relapse or GAD positive enhancement
  • •Secondary progressive MS with relapse
  • •Secondary progressive MS without relapse:progression of disease with 1 point increase of EDSS during last 18 months

排除标准

  • •Pregnancy positive test
  • •Under treatment with cytotoxic drugs at the same time or during last 3 months
  • •Under treatment with immunomodulatory drugs at the same time or during last month
  • •Relapse of disease 30 days or less than 30 days before transplantation
  • •Primary progressive MS with out relapse or GAD positive enhancement

研究组 & 干预措施

cell free media

Placebo Comparator

15 patients with relapsing remitting multiple sclerosis who receive cell free media

干预措施: injection of cell free media (Biological)

mesenchymal stem cell reciepiants

Experimental

Patients with relapsing remitting multiple sclerosis who underwent intravenous injection of mesenchymal stem cells

干预措施: intravenous injection of mesenchymal stem cells (Biological)

结局指标

主要结局

MRI metrics changes

时间窗: 6 months

evaluate the effect of mesenchymal stem cell transplantation on number of GD positive lesions.

Brain atrophy

时间窗: 12 months

evaluate the effect of mesenchymal stem cell transplantation to improve brain atrophy

number of sever relapses

时间窗: 6 months

evaluation the effect of mesenchymal stem cell transplantation on number of sever relapses

EDSS

时间窗: 6 months

Evaluation the effect of mesenchymal stem cells on progression of disease based on EDSS

MSFC

时间窗: 6 months

Evaluation the effect of mesenchymal stem cells transplantation on MSFC

次要结局

  • quality of life(6 months)
  • RAO Test(6 months)
  • intravenous cell transplantation(6 months)

研究者

申办方类型
Other Gov
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验